Targeting CCK receptors in human cancers

Current Topics in Medicinal Chemistry

Volumn 7, Issue 12, 2007, Pages 1239-1242

  Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

CCK agonists; CCK Radioligands; Gastrointestinal cancers; Small cell lung carcinoma; Tumor types

Indexed keywords

CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ[26-33][26 DEXTRO ASPARTIC ACID 28,31 AMINOLEUCINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID]; CHOLECYSTOKININ[26-33][26 DEXTRO ASPARTIC ACID 28,31 AMINOLEUCINE PENTETATE]; DEMOGASTRIN 2; DEMOGASTRIN 2 TC 99; MESSENGER RNA; MINIGASTRIN[1 DEXTRO GLUTAMIC ACID PENTETATE Y 90]; MINIGASTRIN[1 DEXTRO GLUTAMIC ACID PENTETATE]; MINIGASTRIN[1 DEXTRO LEUCINE PENTETATE]; MINIGASTRIN[PENTETATE IN 111]; PENTAGASTRIN; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADVANCED CANCER; ASTROCYTOMA; BREAST ADENOCARCINOMA; BRONCHUS TUMOR; CANCER INCIDENCE; CANCER RESEARCH; DRUG ACCUMULATION; DRUG RECEPTOR BINDING; ENDOMETRIUM CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GRANULOSA CELL TUMOR; HUMAN; ISOTOPE LABELING; LEIOMYOSARCOMA; LUNG SMALL CELL CANCER; MENINGIOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOACTIVITY; REVIEW; THYROID MEDULLARY CARCINOMA;

ANIMALS; HUMANS; NEOPLASMS; RADIOLIGAND ASSAY; RECEPTORS, CHOLECYSTOKININ; TUMOR MARKERS, BIOLOGICAL;

EID: 34447256132     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780960546     Document Type: Review

References (29)

1. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003, 24, 389-427.
2. Gibril, F.; Reynolds, J. C.; Doppman, J. L.; Chen, C. C.; Venzon, D. J.; Termanini, B.; Weber, H. C.; Stewart, C. A.; Jensen, R. T. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann. Intern. Med. 1996, 125, 26-34.
3. Waldherr, C.; Pless, M.; Maecke, H. R.; Schumacher, T.; Crazzolara, A.; Nitzsche, E. U.; Haldemann, A.; Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med. 2002, 43, 610-616.
4. Kwekkeboom, D. J.; Teunissen, J. J.; Bakker, W. H.; Kooij, P. P.; de Herder, W. W.; Feelders, R. A.; van Eijck, C. H.; Esser, J. P.; Kam, B. L.; Krenning, E. P. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005, 23, 2754-2762.
5. Sethi, T.; Herget, T.; Wu, S. V.; Walsh, J. H.; Rozengurt, E. CCK-A and CCK-B receptors are expressed in small cell lung cancer lines and mediate Ca2+ mobilization and clonal growth. Cancer Res. 1993, 53, 5208-5213.
6. Reubi, J. C.; Schaer, J. C.; Waser, B. Cholecystokinin(CCK)-A and CCK-B/ gastnn receptors in human tumors. Cancer Res. 1997, 57, 1377-1386.
7. Reubi, J. C.; Waser, B. Unexpected high incidence of cholecystokinin B/ gastrin receptors in human medullary thyroid carcinomas. Int. J. Cancer 1996, 67, 644-647.
8. Amiri-Mosavi, A.; Ahlman, H.; Tisell, L. E.; Wangberg, B.; Kolby, L.; Forssell-Aronsson, E.; Lundberg, P. A.; Lindstedt, G.; Nilsson, O. Expression of cholecystokinin-B/gastrin receptors in medullary thyroid cancer. Eur. J. Surg. 1999, 165, 628-631.
9. Schaer, J. C.; Reubi, J. C. High gastrin and cholecystokinin (CKK) gene expression in human neuronal, renal and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor content. J. Clin. Endocrinol. Metab. 1999, 84, 233-239.
10. Upp, J. R.; Singh, P.; Townsend, C. M.; Thompson, J. C. The clinical significance of gastrin receptors in human colon cancers. Cancer Res. 1989, 49, 488-492.
11. Goetze, J. P.; Nielsen, F. C.; Burcharth, F.; Rehfeld, J. F. Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer. 2000, 88, 2487-2494.
12. Imdahl, A.; Mantamadiotis, T.; Eggstein, S.; Farthmann, E. H.; Baldwin, G. S. Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. J. Cancer Res. Clin. Oncol. 1995, 121, 661-666.
13. Reubi, J. C.; Waser, B.; Schmassmann, A.; Laissue, J. A. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin, and vasoactive intestinal peptide receptors in gastrointestinal adenocarcinoma samples: where are they really located? Int. J. Cancer 1999, 81, 376-386.
14. Reubi, J. C.; Waser, B.; Gugger, M.; Friess, H.; Kleeff, J.; Kayed, H.; Buchler, M. W.; Laissue, J. A. Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology 2003, 125, 98-106.
15. Dufresne, M.; Seva, C.; Fourmy, D. Cholecystokinin and gastrin receptors. Physiol. Rev. 2006, 86, 805-847.
16. Reubi, J. C.; Waser, B.; Schaer, L C.; Laederach, U.; Erion, J.; Srinivasan, A.; Schmidt, M. A.; Bugaj, J. E. Unsulfated DTPA- and DOTA-CCK analogs as specific high affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur. J. Nucl. Med. 1998, 25, 481-490.
17. 111Inlabeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 1999, 40, 2081-2087.
18. Kwekkcboom, D. J.; Bakker, W. H.; Kooij, P. P.; Erion, J.; Srinivasan, A.; de Jong, M.; Reubi, J. C.; Krenning, E. P. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. 2000, 27, 1312-1317.
19. Behr, T. M.; Jenner, N.; Behe, M.; Angerstein, C.; Gratz, S.; Raue, F.; Becker, W. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J. Nucl. Med. 1999, 40, 1029-1044.
20. Behe, M.; Becker, W.; Gotthardt, M.; Angerstein, C.; Behr, T. M. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1140-1146.
21. Aloj, L.; Caraco, C.; Panico, M.; Zannetti, A.; Del Vecchio, S.; Tesauro, D.; De Luca, S.; Arra, C.; Pedone, C.; Morelli, G.; Salvatore, M. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J. Nucl. Med. 2004, 45, 485-494.
22. Behr, T. M.; Behe, M. P. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002, 32, 97-109.
23. Behe, M.; Roubi, J. C.; Nock, B.; Mäcke, H.; Breeman, W. A. P.; Bernhard, H. F.; Behr, T. M.; De Jong, M. Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, S78.
24. Laverman, P.; Behe, M.; Oyen, W. J.; Willems, P. H.; Corstens, F. H.; Behr, T. M,; Boerman, O. C. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug. Chem. 2004, 15, 561-568.
25. von Guggenberg, E.; Behe, M.; Behr, T. M.; Saurer, M.; Seppi, T.; Decristoforo, C. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glul]-minigastrin. Bioconjug. Chem. 2004, 15, 864-871.
26. Aloj, L.; Panico, M.; Caraco, C.; Del Vecchio, S.; Arra, C.; Affuso, A.; Accardo, A.; Mansi, R.; Tesauro, D.; De Luca, S.; Pedone, C.; Visentin, R.; Mazzi, U.; Morelli, G.; Salvatore, M. In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging. Cancer Biother Radiopharm. 2004, 19, 93-98.
27. Nock, B. A.; Maina, T.; Behe, M.; Nikolopoulou, A.; Gotthardt, M.; Schmitt, J. S.; Behr, T. M.; Macke, H. R. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J. Nucl. Med. 2005, 46, 1727-1736.
28. 111In-DOTA-NOC in medullary thyroid cancer. J. Nucl. Med. 2006, 47, 83P.
29. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Macke, H. R.; Reubi, J. C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA 2006, 103, 16436-16441.